




Newborn Stem Cell Quarterly Review

In case you missed it, here are the top stories that our partner healthcare providers are discussing, along with news about important resources now available to help better support your patients' health.









5 misconceptions about newborn stem cells

Despite its recognized importance in medicine for over 35 years, misconceptions about preserving newborn stem cells persist among the public. To help you provide the most accurate information to your patients, we'd like to clarify some common misconceptions about this process.



Exclusive pricing for the OB/GYN and midwife community


CBR offers you and your staff significant savings on newborn stem cell preservation. Speak to your CBR representative or call Healthcare Provider Support at 1.888.588.0258.



Q1 2024 Newborn Stem Cell Quarterly Review



A SHORT HISTORY OF CBR AND NEWBORN STEM CELLS





Discover why CBR[®] is #1 with OB/GYNs: Explore the data that makes the difference

There's a reason that CBR® is #1 recommended by OB/GYNs7-actually, there are many reasons contributing to our success as a global leader in the newborn stem cell preservation industry.³

This newly updated fact sheet offers a detailed look at the significant advantages CBR offers to parents interested in preserving the powerful healing potential found in their baby's cord blood and cord tissue.



Best practices for newborn stem cell collection

Our experience processing over one million cord blood and cord tissue collections from over 47,000 healthcare providers³ found that following a few important steps may enhance usability of cord blood samples for your patients and their families.

Download our newly updated handout, "Maximize Collection Volume and Minimize Contamination Risk," for a clear, step-by-step guide on how to help ensure a quality collection.





Connect with CBR Looking for more information to support your patients?

We've got you covered. Please visit **cordblood.com/providers** or call **1.888.588.0258** to speak with a representative today.

1. Knudtzon S. Blood. 1974;43:357-361. 2. Gluckman E, et al. N Engl J Med. 1989;321:1174-1178. 3. Internal data on file. 4. Wagner JE. Cord blood 2.0: state of the art and future directions in transplant medicine. Blood Res. 2019 Mar;54(1):7-9. doi: 10.5045/br.2019.541.7. Epub 2019 Mar;21. MNID: 30956957; PMCID: PMC64392997. 5. US National Library of Medicine. ClinicalTrials.gov. Accessed October 21, 2022. https://clinicaltrials.gov/. 6. Broxmeyer H, Luchsinger L, Weinberg R, et al. Cell Rep Med. 2023 Nov 21:+(1): 101259. 7. Blind survey, Egg Strategy, 10/9, funded by CBR.

The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient's medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available.

Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.'s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord-derived stem cells. Cbr Systems, Inc.'s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.